| scholarly article | Q13442814 |
| P2093 | author name string | D Andes | |
| M van Ogtrop | |||
| P2860 | cites work | Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. | Q33695281 |
| In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. | Q33697003 | ||
| Antifungal agents: chemotherapeutic targets and immunologic strategies | Q34400044 | ||
| Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. | Q35136891 | ||
| Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans | Q35572405 | ||
| Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo | Q35652874 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases | Q35997038 | ||
| Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome | Q36528018 | ||
| Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te | Q36855581 | ||
| Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis | Q37069686 | ||
| Pharmacokinetics and tissue penetration of fluconazole in humans | Q37918375 | ||
| Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice | Q39814888 | ||
| Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection | Q39819234 | ||
| Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 | ||
| Pharmacokinetics and pharmacodynamics of antibiotics in otitis media | Q41148314 | ||
| International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections | Q41550505 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Correlation between in vitro and in vivo activity of antifungal agents against Candida species | Q42283580 | ||
| Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance | Q44986554 | ||
| Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 | ||
| In vivo postantibiotic effect in a thigh infection in neutropenic mice | Q70370760 | ||
| The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance | Q71181685 | ||
| A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute | Q72741418 | ||
| The postantibiotic effect of antifungal agents against common pathogenic yeasts | Q72807287 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | candidiasis | Q273510 |
| fluconazole | Q411478 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 2116-2120 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model | |
| P478 | volume | 43 |
| Q92282269 | A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species |
| Q35944927 | Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness |
| Q35688450 | Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy |
| Q35663841 | Antifungal pharmacokinetics and pharmacodynamics |
| Q33972828 | Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome |
| Q33975757 | Antifungal susceptibility testing: practical aspects and current challenges |
| Q37310029 | Antifungal therapeutic drug monitoring: established and emerging indications |
| Q64989502 | Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia? |
| Q35635693 | Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia |
| Q36870712 | Association of fluconazole pharmacodynamics with mortality in patients with candidemia |
| Q43121831 | Association of fluconazole pharmacodynamics with mortality in patients with candidemia |
| Q34597018 | Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children |
| Q37190801 | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin |
| Q35973357 | Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future |
| Q36094974 | Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia |
| Q33938166 | Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans |
| Q37908856 | Current concepts in antifungal pharmacology |
| Q37358623 | Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients |
| Q37356974 | Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection |
| Q34077069 | Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. |
| Q40916536 | Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. |
| Q33980062 | Evaluation of voriconazole pharmacodynamics using time-kill methodology |
| Q90577176 | Extrapolating Antifungal Animal Data to Humans - Is it reliable? |
| Q33938082 | Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. |
| Q30435365 | Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants |
| Q34807770 | Fluconazole loading dose pharmacokinetics and safety in infants |
| Q35746253 | Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. |
| Q33768787 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection |
| Q36281368 | Host contributions to construction of three device-associated Candida albicans biofilms |
| Q34721695 | Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans |
| Q49598880 | In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. |
| Q28344464 | In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida |
| Q46155648 | In vitro human onychopharmacokinetic and pharmacodynamic analyses of ME1111, a new topical agent for onychomycosis |
| Q33979115 | In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model |
| Q34721706 | In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling |
| Q36425025 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| Q36932989 | In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model |
| Q34881309 | In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model |
| Q34881676 | In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model |
| Q35091285 | In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis |
| Q36048229 | In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. |
| Q34647337 | Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing |
| Q37568382 | Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state |
| Q37263435 | Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model |
| Q36482785 | Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans |
| Q35756422 | Nontoxic antimicrobials that evade drug resistance |
| Q34026267 | Novel entries in a fungal biofilm matrix encyclopedia |
| Q33910250 | One year prospective survey of Candida bloodstream infections in Scotland. |
| Q36364100 | Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations |
| Q39092240 | Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection |
| Q35105763 | Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model |
| Q35007030 | Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis |
| Q37756116 | Pharmacokinetic/pharmacodynamic profile of posaconazole |
| Q36520587 | Pharmacokinetic/pharmacodynamic profile of voriconazole |
| Q42577557 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect |
| Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
| Q27025299 | Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications |
| Q37026726 | Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints |
| Q92953639 | Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels |
| Q42284150 | Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers |
| Q33980421 | Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis |
| Q58783779 | Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO |
| Q92613666 | Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis |
| Q56910086 | Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis |
| Q30439710 | Population pharmacokinetics of fluconazole in young infants |
| Q36505539 | Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis |
| Q91876531 | Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans |
| Q34595925 | Rat indwelling urinary catheter model of Candida albicans biofilm infection |
| Q35912756 | Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents |
| Q36887950 | Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms. |
| Q36095050 | The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q34510556 | Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
Search more.